Scientific Letters
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: January 20, 2024
Accepted: March 8, 2024
Accepted: March 8, 2024
1130
Views
1622
Downloads
51
HTML
Authors
Not applicable.
Downloads
Download data is not yet available.
Citations
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide,
Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. April
;376(14):1311–20.
Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous
Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the
BMT CTN 0702 Trial. J Clin Oncol. March 2019;37(7):589–97.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous
haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or
without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide
maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised,
open-label, phase 3 study. Lancet Haematol. June 2020;7(6):e456–68.
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al.
International myeloma working group (IMWG) consensus statement and guidelines regarding
the current status of stem cell collection and high-dose therapy for multiple myeloma and the
role of plerixafor (AMD 3100). Leukemia. October 2009;23(10):1904–12.
Sánchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al.
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low
circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow
Transplant. January 2015;50(1):34–9.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide,
and dexamethasone with or without daratumumab before and after autologous stem-cell
transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-
label, phase 3 study. Lancet. July 2019;394(10192):29–38.
Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, et al. Stem cell yield and
transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving
daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica. August 2021;106(8):2257–60.
Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Migkou M, Gavriatopoulou M, Ntanasis-
Stathopoulos I, et al. Impact of daratumumab on stem cell mobilization and collection,
engraftment and early post-transplant complications among multiple myeloma patients
undergoing autologous stem cell transplantation. Leukemia & Lymphoma. September
;0(0):1–8.
Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma:
a systematic review and meta-analysis. J Int Med Res. August 2021;49(8):03000605211038135.
How to Cite
“Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024041. doi:10.4084/MJHID.2024.041.
Copyright (c) 2024 Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
